Neoplasm metastasis Trials in Shanghai, China
Conditions / Neoplasm metastasis / Shanghai, China
Neoplasm metastasis has been the subject of sustained clinical investigation across multiple research sites.
17 total trials for this combination
Showing top 10 of 17 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT00781612 | A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies | ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT07213804 | A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer | RECRUITING | — |
| NCT07218380 | A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract | RECRUITING | — |
| NCT05614739 | FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3 | RECRUITING | PHASE1 |
| NCT06119581 | A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer | RECRUITING | PHASE3 |
| NCT05288166 | A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT07213804 | A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer | RECRUITING | — |
| NCT07218380 | A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract | RECRUITING | — |
| NCT07174336 | A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) | RECRUITING | — |
| NCT07218380 | A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract | RECRUITING | — |